Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Leukemia ; 33(11): 2710-2719, 2019 11.
Artigo em Inglês | MEDLINE | ID: mdl-31462732

RESUMO

This phase 3 trial compared tandem autologous stem cell transplantation (autoSCT) versus autoSCT followed by reduced-intensity conditioning allogeneic stem cell transplantation (auto/alloSCT) in patients with newly diagnosed multiple myeloma (MM) with deletion of (del) chromosome 13q (del13q). The availability/absence of a human leukocyte antigen-matched-related or matched-unrelated donor (MUD) determined the nature of the second SCT. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population (n = 199). Auto/alloSCT was performed in 126 patients; 74 received MUD allografts. After 91 months median follow-up, median PFS with auto/allo versus tandem autoSCT was 34.5 versus 21.8 months (P = 0.003; adjusted hazard ratio 0.55, 95% confidence interval 0.36-0.84). Median overall survival (OS) was 70.2 versus 71.8 months (P = 0.856). Two-year non-relapse mortality with auto/allo versus tandem autoSCT was 14.3% versus 4.1% (P = 0.008). In patients harboring both del13q and del17p, median PFS and OS were 37.5 and 61.5 months with auto/allo (n = 19) versus 6.1 and 23.4 months with tandem autoSCT (n = 6) (P = 0.0002 and 0.032). Our findings suggest that auto/alloSCT significantly extends PFS versus tandem autoSCT in del13q MM, and indicate some survival benefit for first-line alloSCT in high-risk MM.


Assuntos
Mieloma Múltiplo/genética , Mieloma Múltiplo/terapia , Transplante Homólogo , Adulto , Deleção Cromossômica , Citogenética , Intervalo Livre de Doença , Feminino , Seguimentos , Doença Enxerto-Hospedeiro , Antígenos HLA/química , Humanos , Masculino , Pessoa de Meia-Idade , Modelos de Riscos Proporcionais , Condicionamento Pré-Transplante , Resultado do Tratamento
3.
PLoS One ; 8(12): e81360, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24363809

RESUMO

LILRA3 is the sole soluble member of the LILR family. Previous studies from our group had shown that a 6.7 kb genetic deletion of LILRA3 is associated with MS and Sjögren's syndrome. An impairment of the immune response leads to a predisposition for B-NHL, so we wanted to study whether the deletion of LILRA3 is also a risk factor for B-NHL, as well as the function of LILRA3. We discovered that the frequency of the homozygous LILRA3 deletion was significantly higher in B-NHL (6%) than in blood donors (3%) (P = 0.03). We detected binding of fluorochrome-conjugated recombinant LILRA3 to monocytes and B-cells. Incubation of PBMCs with recombinant LILRA3 induced proliferation of CD8(+) T-cells and NK cells, as determined by CFSE staining. Using a transwell system, we demonstrated that LILRA3-stimulated lymphocyte proliferation was mediated by monocytes and required both cell contact and soluble factors. Secretion of IL-6, IL-8, IL-1ß and IL-10 in the cell supernatant was stimulated by LILRA3. We conclude that LILRA3 is an immunostimulatory molecule, whose deficiency is associated with higher frequency of B-NHL.


Assuntos
Adjuvantes Imunológicos/genética , Deleção de Genes , Ativação Linfocitária/imunologia , Linfoma de Células B/genética , Receptores Imunológicos/genética , Adjuvantes Imunológicos/metabolismo , Linfócitos B/metabolismo , Linfócitos T CD8-Positivos/imunologia , Feminino , Fluoresceínas , Corantes Fluorescentes/metabolismo , Alemanha , Humanos , Linfoma de Células B/imunologia , Masculino , Monócitos/metabolismo , Receptores Imunológicos/metabolismo , Proteínas Recombinantes/metabolismo , Succinimidas , Trítio
4.
J Clin Neurosci ; 18(7): 978-80, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21565511

RESUMO

We report a patient diagnosed with a B-cell lymphoma after detecting monoclonal B-cells in the cerebrospinal fluid (CSF) and who had only minimal symptoms and a benign course. A 46-year-old man experienced three transitory episodes with neurological symptoms. On examination papilledema in both eyes was found. Flow cytometry (FACS)-analysis detected monoclonal B-cells in the CSF as well as in the peripheral blood and the bone marrow. Results were consistent with a low-risk lymphoma, most probably a marginal zone B-cell lymphoma. Interestingly, our patient had no progressive clinical symptoms and remained without specific therapy during 36 months of follow-up. Nevertheless, CSF-analysis led to the diagnosis of the B-cell lymphoma.


Assuntos
Leucocitose/líquido cefalorraquidiano , Linfoma de Células B/líquido cefalorraquidiano , Linfoma de Células B/patologia , Anomia/etiologia , Anti-Hipertensivos/uso terapêutico , Separação Celular , Dermatomiosite/patologia , Citometria de Fluxo , Cefaleia/etiologia , Humanos , Hipertensão/complicações , Hipertensão/tratamento farmacológico , Hipestesia/etiologia , Imunofenotipagem , Linfoma de Células B/complicações , Masculino , Pessoa de Meia-Idade , Debilidade Muscular/etiologia , Papiledema/etiologia , Distúrbios da Fala/etiologia , Esplenomegalia/patologia , Transtornos da Visão/etiologia
5.
J Med Microbiol ; 57(Pt 3): 384-387, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18287305

RESUMO

In addition to Legionella pneumophila, about 20 Legionella species have been documented as human pathogens. The majority of infections by non-pneumophila Legionella species occur in immunocompromised and splenectomized patients. Here, we report a case of 'classical' lobar pneumonia caused by Legionella longbeachae in a splenectomized patient receiving corticosteroids for chronic immune thrombocytopenia. Tests for Legionella antigen were negative. L. longbeachae was immediately detected in bronchoalveolar fluid by PCR and subsequently confirmed by culture on legionella-selective media. The features of Legionnaires' disease in immunocompromised patients with special emphasis on significance and detection of non-pneumophila species are reviewed.


Assuntos
Hospedeiro Imunocomprometido , Legionella longbeachae/isolamento & purificação , Legionelose/microbiologia , Pneumonia Bacteriana/microbiologia , Idoso , Líquido da Lavagem Broncoalveolar/microbiologia , Meios de Cultura , Humanos , Legionella longbeachae/classificação , Legionella longbeachae/genética , Masculino , Reação em Cadeia da Polimerase
6.
Ann Allergy Asthma Immunol ; 98(3): 294-8, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17378264

RESUMO

BACKGROUND: The functional importance of CD2 in vivo is currently the subject of discussion. OBJECTIVE: To describe a 47-year-old white man with systemic Rhodococcus infection, a rarely observed opportunistic disease, secondary to severe lymphopenia. METHODS: We extensively characterized lymphocyte phenotype and function. RESULTS: Both CD4+ and CD8+ T cells were severely diminished, with a particular reduction in alpha:beta T cells. Human immunodeficiency virus infection was excluded. CD2 expression was decreased not only on T cells but also on nonaffected natural killer cells. Production of interferon-gamma interleukin 2, and tumor necrosis factor a was normal. Neither B-cell numbers nor humoral immune responses were affected. In addition, adhesion molecules CD11a, CD54, and CD154 were normally expressed, as were the costimulatory molecules CD28, CD80, and CD86. CONCLUSIONS: We hypothesize that prolonged disturbance of CD2 expression led to an acquired severe cellular immunodeficiency. This underlines the importance of CD2 in vivo, where it may play a role in the fine regulation of T-cell proliferation.


Assuntos
Infecções por Actinomycetales/imunologia , Antígenos CD2 , Linfopenia/imunologia , Rhodococcus/imunologia , Linfócitos T/patologia , Infecções por Actinomycetales/complicações , Antígenos CD2/biossíntese , Células Cultivadas , Humanos , Linfopenia/etiologia , Masculino , Pessoa de Meia-Idade , Linfócitos T/imunologia , Linfócitos T/metabolismo
8.
Br J Haematol ; 130(6): 912-25, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16156861

RESUMO

The high incidence of activating RAS mutations, coupled with accumulating evidence linking RAS to multiple myeloma (MM) pathogenesis, indicate that novel therapies utilising inhibitors of RAS prenylation and signalling may be successful in the management of this disease. While preclinical studies investigating prenylation inhibitors, such as lovastatin, farnesyltransferase inhibitors (FTI) and geranylgeranyltransferase inhibitors (GGTI), have been promising, recent phase I/II clinical trials with FTI R115777 were disappointing, suggesting resistance to FTI monotherapy. To address this issue, the effects of FTI, GGTI and lovastatin alone and in combination were analysed in MM cell lines and primary cells. FTI treatment blocked H-RAS processing, but was ineffective at inhibiting K- and N-RAS prenylation because of alternative geranylgeranylation of these isoforms. However, combinations of FTI and GGTI or lovastatin were found to synergistically inhibit MM cell proliferation, migration, K- and N-RAS processing, RAS-to-mitogen-activated protein kinase signalling and to induce apoptosis. In contrast to FTI, lovastatin and some GGTI were found to cause intracellular accumulation of Rho proteins. Our results suggest that clinical efficacy of prenylation inhibitors in MM are limited by alternative prenylation of several small G-proteins, such as RhoB, K- and N-RAS. Furthermore, strategies combining FTI with GGTI or statins may provide greater efficacy in MM treatment.


Assuntos
Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Mieloma Múltiplo/patologia , Prenilação de Proteína/efeitos dos fármacos , Adulto , Alquil e Aril Transferases/antagonistas & inibidores , Morte Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Movimento Celular/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Farnesiltranstransferase , Genes ras , Humanos , Lovastatina/farmacologia , Mieloma Múltiplo/metabolismo , Células Tumorais Cultivadas , Proteínas ras/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...